financetom
Business
financetom
/
Business
/
Why Dakota Gold Shares Are Trading Lower
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Dakota Gold Shares Are Trading Lower
Mar 21, 2025 11:08 AM

Dakota Gold Corp ( DC ) shares are trading lower by 8.1% to $2.81 during Friday’s session following its announcement and pricing of a $35 million common stock offering.

What To Know: Dakota Gold ( DC ) has priced its public offering of 12.4 million common shares at $0.001 par value, expected to close by March 24, pending regulatory approval.

The offering will generate approximately $35 million in gross proceeds, with an option for underwriters to purchase an additional 1.86 million shares, potentially raising total proceeds to $40 million. The funds will support working capital and general corporate purposes.

What Else: The total gross proceeds of $35 million from 12.4 million shares suggest an estimated offering price of approximately $2.82 per share.

BMO Capital Markets leads the offering, with Canaccord Genuity, CIBC Capital Markets, RBC Capital Markets, Scotiabank and Agentis Capital Markets as co-managers. Underwriters have 30 days to exercise their option for additional shares.

Read Also: ‘Monster Equity Inflows Say No One Really Believes Trade War,’ Bank Of America’s Hartnett Says

How To Buy DC Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Dakota Gold’s case, it is in the Materials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

According to data from Benzinga Pro, DC has a 52-week high of $3.50 and a 52-week low of $1.84.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Nordstrom to Open New Nordstrom Rack Store in New York
Nordstrom to Open New Nordstrom Rack Store in New York
Jan 30, 2025
10:46 AM EST, 01/30/2025 (MT Newswires) -- Nordstrom (JWN) said Thursday it plans to open a new Nordstrom Rack store in Lake Grove, New York, this fall. The store, which will be about 25,000 square feet, will be located in Smith Haven Plaza, the fashion retailer said. Price: 24.30, Change: +0.08, Percent Change: +0.31 ...
iHeartMedia Signs Deal to Become Sales Partner for BBC Podcasts in US
iHeartMedia Signs Deal to Become Sales Partner for BBC Podcasts in US
Jan 30, 2025
10:46 AM EST, 01/30/2025 (MT Newswires) -- iHeartMedia (IHRT) and BBC Studios said Thursday that they have signed a multi-year deal under which iHeartMedia will become the third-party advertising reseller of the British broadcaster's podcasts in the US. Financial details of the deal were not provided. ...
Walmart Canada to invest more than $4 billion to expand stores, supply chain
Walmart Canada to invest more than $4 billion to expand stores, supply chain
Jan 30, 2025
(Reuters) - Walmart Canada said on Thursday it is investing about C$6.5 billion ($4.51 billion) to build new stores and expand its supply chain, marking its biggest ever investment since opening its first store nearly 30 years ago. U.S. retail giant Walmart's Canadian branch, which plans to expand its footprint, added it would be building dozens of new stores starting...
Kazia Therapeutics Shares Rise After Breast Cancer Treatment Trial Announced
Kazia Therapeutics Shares Rise After Breast Cancer Treatment Trial Announced
Jan 30, 2025
10:45 AM EST, 01/30/2025 (MT Newswires) -- Kazia Therapeutics' ( KZIA ) shares jumped 55% in recent Thursday trading after the company announced the regulatory approval and launch of a clinical trial evaluating the combination of its investigational drug paxalisib and immunotherapy in patients with advanced breast cancer. The multi-center, open-label phase 1b study will assess the safety and efficacy...
Copyright 2023-2026 - www.financetom.com All Rights Reserved